References
- . Kessler RC, Berglund P, Dernier O, . The epidemiology of major depressive disorder: Results from the national comorbidity survey replication (NCS-R). JAMA. 2003;289(23):3095–3105
- . Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatry. 1992;49(10):831–834
- . von Knorring L. Depression—a serious, lifelong but treatable illness. Nord Med. 1996;111(8):259–263
- . Cassano P, Fava M. Depression and public health: An overview. JPsychosom Res. 2002;53(4):849–857
- . Cadieux RJ. Practical management of treatment-resistant depression. Am Fam Physician. 1998;58(9):2059–2062
- . Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23–29
- . Gaynes BN, Lux L, Lloyd S, . Nonpharmacologic interventions for treatment-resistant depression in adults; comparative effectiveness review no.33. Rockville, MD: Agency for Healthcare Research and Quality; 2011;11-EHC056-EF
- . Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: Report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. Electroencephalogr Clin Neurophysiol. 1998;108(1):1–16
- . Walter G, Martin J, Kirkby K, Pridmore S. Transcranial magnetic stimulation: Experience, knowledge and attitudes of recipients. Aust N Z J Psychiatry. 2001;35(1):58–61
- . Mayo Foundation for Medical Education and Research. Tests and procedures: Transcranial magnetic stimulation, http://www.mayoclinic.com/health/transcranial-magnetic-stimulation/MY00185. Accessed October, 2011
- . Belmaker B, Fitzgerald P, George MS, . Managing the risks of repetitive transcranial stimulation. CNS Spectr. 2003;8(7):489
- . US Food and Drug Administration, US Department of Health and Human Services. 510(k) premarket notification summary: Neurostar(R) TMS therapy system, http://www.accessdata.fda.gov/cdrh_docs/pdf8/K083538.pdf. Accessed October 15, 2011
- . Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: Systematic reviews and economic modelling studies. Health Technol Assess. 2005;9(9):1–156, iii-iv
- . Mayo Foundation for Medical Education and Research. Tests and procedures: Electroconvulsive therapy (ECT). http://www.mayoclinic.com/health/electroconvulsive-therapy/MY00129. Accessed October, 2011
- . O'Connor M, Brenninkmeyer C, Morgan A, . Relative effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy on mood and memory: A neurocognitive risk-benefit analysis. Cogn Behav Neurol. 2003;16(2): 118–127
- . Lulic D, Ahmadian A, Baaj AA, Benbadis SR, Vale FL. Vagus nerve stimulation. Neurosurg Focus. 2009;27(3):E5
- . Mayo Foundation for Medical Education and Research. Diseases and conditions: Vagus nerve stimulation for depression. http://www.mayoclinic.com/health/vagus-nerve-stimulation/MYOO183. Accessed October 15, 2011
- . George MS, Rush AJ, Marangell LB, . A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58(5):364–373
- . Rush AJ, Siefert SE. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Exp Neurol. 2009;219(1):36–43
- . US Food and Drug Administration, Center for Devices and Radiological Health. Premarket approval application (PMA) supplement: VNS therapy system (Cyberonics, Inc.). http://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s050a.pdf. Accessed October 15, 2011
- . Mayo Foundation for Medical Education and Research. Tests and procedures: Cognitive behavioral therapy, http://www.mayoclinic.com/health/cognitive-behavioral-therapy/MY00194. Accessed October 15, 2011
- . Swartz H. Interpersonal therapy. In: Hersen M, Bellack AS, eds. Handbook of Comparative Interventions for Adult Disorders. 2nd ed. New York: John Wiley and Sons, Inc.; 1999:139–159
- . Markowitz JC, Weissman MM. Interpersonal psychotherapy: Principles and applications. World Psychiatry. 2004;3(3):136–139
- . Berlim MT, McGirr A Beaulieu M, Turecki G. High frequency repetitive transcranial magnetic stimulation as an augmenting strategy in severe treatment-resistant major depression: A prospective 4-week naturalistic trial. J Affective Disord. 2011;130(1–2):312–317
- . Oulis P, Florakis A, Markatou M, Tzanoulinos G, Masdrakis VG. Corrected QT interval changes during electroconvulsive therapy-antidepressants-atypical antipsychotics coadministration: Safety issues. JECT. 2011;27(1):e4–e6
- . NHIC, Corp. Local Coverage Determination (LCD): Repetitive Transcranial Magnetic Stimulation (rTMS) (L32228). http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=32228&ContrId=211&ver=3&ContrVer=1&CntrctrSelected=211*1&Cntrctr=211&name=NHIC%2c+Corp.+(14502%2c+MAC+-+Part+B)&DocType=Active&DocStatus=Draft&s=55&bc=AggAAAIAAAAAAA%3d%3d&. Accessed April 1, 2013
- . Anthem. Medical Policy BEH.00002, Transcranial Magnetic Stimulation for Depression and Other Neuropsychiatric Disorders. http://www.anthem.com/medicalpolicies/policies/mp_pw_a047769.htm. Accessed April 1, 2013
- . Cahaba Government Benefit Administrators. Local Coverage Determination (LCD): Medicine: Repetitive Transcranial Magnetic Stimulation (rTMS) for Resistant Depression (L32834). http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=32834&ver=4&ContrId=213&ContrVer=1. Accessed April 1, 2013